cell cycle regulator cyclins Search Results


anti cdkn2a p16ink4a affinity  (MedChemExpress)
93
MedChemExpress anti cdkn2a p16ink4a affinity
Anti Cdkn2a P16ink4a Affinity, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cdkn2a p16ink4a affinity/product/MedChemExpress
Average 93 stars, based on 1 article reviews
anti cdkn2a p16ink4a affinity - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
cdkn2a  (ProSci Incorporated)
90
ProSci Incorporated cdkn2a
Genetic alterations in NPC-PDX tumors. ( a ) Copy number variations (CNV) of NPC-PDX tumors versus corresponding patient’s peripheral blood mononuclear cells (PBMC). Genome-wide CNV alterations in four paired PDX tumor samples (ST, LN, LG and LV). CCND1 CNV gain (red arrow) and <t>CDKN2A</t> CNV loss (green arrow) are indicated. ( b ) HE and EB virus-encoded small RNA (EBER) staining of parental NPC tumor with bone metastasis and its derived NPC-PDX. ( c ) CNV profile comparisons of NPC FFPE-Bone and PDX-Bone based on WES and ( d ) ultra-deep sequencing of cancer panel-409 are shown (genes associated with or without copy number alteration are indicated in different colors or in grey, respectively). Observed copy number for each evaluated position is shown on the y-axis as a log 2 scale. Correlation plots with Pearson’s correlation coefficient, r, indicating similarities between two CNV profiles
Cdkn2a, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdkn2a/product/ProSci Incorporated
Average 90 stars, based on 1 article reviews
cdkn2a - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cyclins and cell cycle regulation  (BioCarta)
90
BioCarta cyclins and cell cycle regulation
Top ten pathways identified by pathway enrichment analysis for miR-30a and -191 .
Cyclins And Cell Cycle Regulation, supplied by BioCarta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyclins and cell cycle regulation/product/BioCarta
Average 90 stars, based on 1 article reviews
cyclins and cell cycle regulation - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cell cycle regulator cyclins  (CEM Corporation)
90
CEM Corporation cell cycle regulator cyclins
Top ten pathways identified by pathway enrichment analysis for miR-30a and -191 .
Cell Cycle Regulator Cyclins, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell cycle regulator cyclins/product/CEM Corporation
Average 90 stars, based on 1 article reviews
cell cycle regulator cyclins - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cell cycle mutants such as cyclin a, regulator of cyclin a or string  (Credence Genomics)
90
Credence Genomics cell cycle mutants such as cyclin a, regulator of cyclin a or string
Top ten pathways identified by pathway enrichment analysis for miR-30a and -191 .
Cell Cycle Mutants Such As Cyclin A, Regulator Of Cyclin A Or String, supplied by Credence Genomics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell cycle mutants such as cyclin a, regulator of cyclin a or string/product/Credence Genomics
Average 90 stars, based on 1 article reviews
cell cycle mutants such as cyclin a, regulator of cyclin a or string - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Genetic alterations in NPC-PDX tumors. ( a ) Copy number variations (CNV) of NPC-PDX tumors versus corresponding patient’s peripheral blood mononuclear cells (PBMC). Genome-wide CNV alterations in four paired PDX tumor samples (ST, LN, LG and LV). CCND1 CNV gain (red arrow) and CDKN2A CNV loss (green arrow) are indicated. ( b ) HE and EB virus-encoded small RNA (EBER) staining of parental NPC tumor with bone metastasis and its derived NPC-PDX. ( c ) CNV profile comparisons of NPC FFPE-Bone and PDX-Bone based on WES and ( d ) ultra-deep sequencing of cancer panel-409 are shown (genes associated with or without copy number alteration are indicated in different colors or in grey, respectively). Observed copy number for each evaluated position is shown on the y-axis as a log 2 scale. Correlation plots with Pearson’s correlation coefficient, r, indicating similarities between two CNV profiles

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

doi: 10.1186/s13046-018-0873-5

Figure Lengend Snippet: Genetic alterations in NPC-PDX tumors. ( a ) Copy number variations (CNV) of NPC-PDX tumors versus corresponding patient’s peripheral blood mononuclear cells (PBMC). Genome-wide CNV alterations in four paired PDX tumor samples (ST, LN, LG and LV). CCND1 CNV gain (red arrow) and CDKN2A CNV loss (green arrow) are indicated. ( b ) HE and EB virus-encoded small RNA (EBER) staining of parental NPC tumor with bone metastasis and its derived NPC-PDX. ( c ) CNV profile comparisons of NPC FFPE-Bone and PDX-Bone based on WES and ( d ) ultra-deep sequencing of cancer panel-409 are shown (genes associated with or without copy number alteration are indicated in different colors or in grey, respectively). Observed copy number for each evaluated position is shown on the y-axis as a log 2 scale. Correlation plots with Pearson’s correlation coefficient, r, indicating similarities between two CNV profiles

Article Snippet: Antibodies used in this study: RB1 (CusaBio PA003948), RB-P (Cell Signaling 9307), E2F1 (Santa Cruz SC-193), CDK2 (CusaBio PA001533), CDK4 (Santa Cruz SC-23896), CDK6 (Santa Cruz SC-53638), CCND1 (Santa Cruz SC-8396), CCNE2 (Proteintech 11,935–1-AP), CDKN2A (Prosci 4211), CDKN1A (Santa Cruz SC-6246), PCNA (Proteintech 10,205–2-AP) and GAPDH (Santa Cruz FL-335).

Techniques: Genome Wide, Virus, Staining, Derivative Assay, Sequencing

CCND1 mRNA expression and IHC staining in NPC patients and PDX tumors. ( a ) The expression fold change of candidate genes ( CCND1, CDKN2A and CDKN2B ) are indicated based on the cDNA microarray data of five PDX tissues, and C666–1 (EBV-positive NPC cells) and NP69 (immortalized normal nasopharyngeal cells, as control) cell lines. ( b ) Agarose gel electrophoresis of RT-PCR products of CCND1 in PBMC, two NPC cell lines and five PDXs (GAPDH serves as an internal control). Cyclin D1 IHC staining in ( c ) NPC no.13 patient, with NPC primary site, NPC metastatic to bone, and PDX-Bone tumor and ( d ) NPC no.2 patient, with NPC metastatic to lymph node, and PDX-LN tumor

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

doi: 10.1186/s13046-018-0873-5

Figure Lengend Snippet: CCND1 mRNA expression and IHC staining in NPC patients and PDX tumors. ( a ) The expression fold change of candidate genes ( CCND1, CDKN2A and CDKN2B ) are indicated based on the cDNA microarray data of five PDX tissues, and C666–1 (EBV-positive NPC cells) and NP69 (immortalized normal nasopharyngeal cells, as control) cell lines. ( b ) Agarose gel electrophoresis of RT-PCR products of CCND1 in PBMC, two NPC cell lines and five PDXs (GAPDH serves as an internal control). Cyclin D1 IHC staining in ( c ) NPC no.13 patient, with NPC primary site, NPC metastatic to bone, and PDX-Bone tumor and ( d ) NPC no.2 patient, with NPC metastatic to lymph node, and PDX-LN tumor

Article Snippet: Antibodies used in this study: RB1 (CusaBio PA003948), RB-P (Cell Signaling 9307), E2F1 (Santa Cruz SC-193), CDK2 (CusaBio PA001533), CDK4 (Santa Cruz SC-23896), CDK6 (Santa Cruz SC-53638), CCND1 (Santa Cruz SC-8396), CCNE2 (Proteintech 11,935–1-AP), CDKN2A (Prosci 4211), CDKN1A (Santa Cruz SC-6246), PCNA (Proteintech 10,205–2-AP) and GAPDH (Santa Cruz FL-335).

Techniques: Expressing, Immunohistochemistry, Microarray, Control, Agarose Gel Electrophoresis, Reverse Transcription Polymerase Chain Reaction

Correlation of CNV of CCND1, CDKN2A and RAD52 with high EBV copy number in 22 NPC plasma. ( a ) CNV of CCND1 , CDKN2A and RAD52 in 22 NPC plasma with high EBV DNA load (> 5000 copies/ml) based on Q-PCR results. ( b ) Correlation plot between CNV of CCND1 , CDKN2A and RAD52 and log EBV DNA load in 22 NPC plasma samples ( c ) Correlation between CNV of the CCND1 / CDKN2A ratio and log EBV load in 22 NPC plasma. Pearson’s correlation coefficient, r, and equations of regression are indicated

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

doi: 10.1186/s13046-018-0873-5

Figure Lengend Snippet: Correlation of CNV of CCND1, CDKN2A and RAD52 with high EBV copy number in 22 NPC plasma. ( a ) CNV of CCND1 , CDKN2A and RAD52 in 22 NPC plasma with high EBV DNA load (> 5000 copies/ml) based on Q-PCR results. ( b ) Correlation plot between CNV of CCND1 , CDKN2A and RAD52 and log EBV DNA load in 22 NPC plasma samples ( c ) Correlation between CNV of the CCND1 / CDKN2A ratio and log EBV load in 22 NPC plasma. Pearson’s correlation coefficient, r, and equations of regression are indicated

Article Snippet: Antibodies used in this study: RB1 (CusaBio PA003948), RB-P (Cell Signaling 9307), E2F1 (Santa Cruz SC-193), CDK2 (CusaBio PA001533), CDK4 (Santa Cruz SC-23896), CDK6 (Santa Cruz SC-53638), CCND1 (Santa Cruz SC-8396), CCNE2 (Proteintech 11,935–1-AP), CDKN2A (Prosci 4211), CDKN1A (Santa Cruz SC-6246), PCNA (Proteintech 10,205–2-AP) and GAPDH (Santa Cruz FL-335).

Techniques: Clinical Proteomics

Top ten pathways identified by pathway enrichment analysis for miR-30a and -191 .

Journal: PLoS ONE

Article Title: Overexpression of MicroRNA miR-30a or miR-191 in A549 Lung Cancer or BEAS-2B Normal Lung Cell Lines Does Not Alter Phenotype

doi: 10.1371/journal.pone.0009219

Figure Lengend Snippet: Top ten pathways identified by pathway enrichment analysis for miR-30a and -191 .

Article Snippet: BioCarta , Cyclins and Cell Cycle Regulation , 0.0013.

Techniques: Gene Expression, Control